Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
Interventions
Olanzapine, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Conditions
Substance Abuse, Bipolar Depression
Interventions
divalproex sodium ER, risperidone
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Conditions
Patients Already Taking Risperidone for Clinical Indications
Interventions
Risperidone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
4 Years to 14 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Columbus, Ohio
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions
Metformin
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Oculomotor and Spatial Cognition Deficits in Schizophrenia

NCT00931996
Conditions
Schizophrenia
Interventions
Antipsychotic
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
15 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Understanding Sleep Problems in Children With Autism Spectrum Disorder

NCT00691080
Conditions
Sleep Problems
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
4 Years to 9 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Houston, Texas
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LYN-005, Risperidone
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions
quetiapine, olanzapine, risperidone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Schizotypal Personality Disorder
Interventions
Risperidone, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Conditions
Schizophrenia
Interventions
TV-46000, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years to 65 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
67
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more
Conditions
Schizophrenia
Interventions
Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Cerritos, California • National City, California • San Diego, California + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies

NCT00937716
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Not applicable Interventional Results available

Omega-3 Dietary Supplements in Schizophrenia

NCT01786239
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions
Risperidone, Omega-3 capsules, Placebo
Drug
Lead sponsor
Delbert Robinson
Other
Eligibility
15 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Schizophrenia
Interventions
Risperidone, Paliperidone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Irvine, California
Conditions
Cocaine-Related Disorders
Interventions
Risperidone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Autism
Interventions
Risperidone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 16 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2Phase 3 Interventional

Risperidone Augmentation for PTSD

NCT00215241
Conditions
Post-Traumatic Stress Disorder
Interventions
sertraline and risperidone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Atlanta, Georgia • Charleston, South Carolina
Conditions
Schizophrenia, Schizoaffective
Interventions
Consta Club
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 4 Interventional Results available

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482
Conditions
Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions
risperidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more